Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant‐Ineligible Patients With Multiple Myeloma

Autor:	Doris K. Hansen, Santosh Gautam, Marie‐Hélène Lafeuille, Carmine Rossi, Bronwyn Moore, Anabelle Tardif‐Samson, Philippe Thompson‐Leduc, Alex Z. Fu, Annelore Cortoos, Shuchita Kaila, Rafael Fonseca
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	bortezomib daratumumab drug therapy health care hematologic diseases multiple myeloma Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Cancer Medicine, Vol 13, Iss 21, Pp n/a-n/a (2024)
Druh dokumentu:	article
ISSN:	2045-7634
DOI:	10.1002/cam4.70308
Popis:	ABSTRACT Introduction Daratumumab, lenalidomide, and dexamethasone (DRd) and bortezomib, lenalidomide, and dexamethasone (VRd) are the only preferred treatment regimens for patients with transplant‐ineligible (TIE) newly diagnosed multiple myeloma (NDMM). As there are no randomized head‐to‐head studies of DRd versus VRd, this analysis aimed to compare real‐world time‐to‐next‐treatment (TTNT) or death in this population. Methods Patients with NDMM who received front‐line (FL) DRd or VRd were identified from the Acentrus database (January 1, 2018 to May 31, 2023). Those with a record of a stem cell transplant or aged
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/801902035fdd43bb97b917d0bf035504 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.